Abstract Purpose Proton pump inhibitors (PPIs) reduce acid secretion in the stomach and
rank as one of the most widely used acid-suppressing medicines globally. While PPIs are …

Gastric cancer is still an important disease causing many deaths worldwide, although there
has been a marked reduction in prevalence during the last few decades. The decline in …

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an
increased risk of gastric cancer compared with new users of histamine-2 receptor …

Helicobacter pylori Infection is formally recognised as an infectious disease, an entity that is
now included in the International Classification of Diseases 11th Revision. This in principle …

Helicobacter pylori infection is still the main risk factor for the development of gastric cancer
(GC). We explore the scientific evidence for the role of the gastric microbiome beyond …

Gastric cancer is considered to be a type of gastrointestinal tumor and is mostly
accompanied by Helicobacter pylori (HP) infection at the early stage. Hence, the long-term …

Background Statin treatment increases the risk of new-onset diabetes mellitus (NODM);
however, data directly comparing the risk of NODM among individual statins is limited. We …

Background A complex microbiota in the gastric mucosa (GM) has been unveiled recently
and its dysbiosis is identified to be associated with gastric cancer (GC). However, the …

Summary Background Proton‐pump inhibitors (PPIs) are suspected to increase the risk of
gastric cancer. Aim To assess the risk of gastric cancer associated with the use of PPIs …

Background: Proton pump inhibitors (PPI) are generally considered to be one of the well-
established prescription drug classes and are commonly used to treat most acid-related …